2、结合合作协议的约定，严格对照《上市公司收购管理办法》第八十四条 规定，逐条分析合作协议解除后，汇垠澳丰能否控制你公司，公司控制权的归属 情况及认定依据。请你公司独立董事核实并发表明确意见。 经查阅《合作协议》的相关约定，公司独立董事认为，在《合作协议》有效 期内，汇垠澳丰根据北京首拓融汇的咨询意见及投资建议行使其作为汇垠日丰普 通合伙人、执行事务合伙人及信托计划投资顾问所拥有的上市公司股东权利，而 北京首拓融汇通过向汇垠澳丰提供咨询意见及投资建议间接控制皓宸医疗 23.81% 股份对应的表决权。 皓宸医疗科技股份有限公司独立董事 关于深圳证券交易所关注函相关问题的独立意见 按照《上市公司独立董事规则》、《深圳证券交易所股票上市规则》、《皓宸医 疗科技股份有限公司章程》、《独立董事工作制度》等有关规定，作为皓宸医疗科 技股份有限公司（以下简称"公司"、"上市公司"或"皓宸医疗"）的独立董事， 本着审慎、负责的态度，就深圳证券交易所关注函的相关问题进行了仔细的核查， 现发表独立意见如下： 1、北京首拓是否认可上述合作协议解除事项，请你公司独立董事核实并发 表明确意见。 经了解，公司向北京首拓融汇投资有限公司（ ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2023-042 皓宸医疗科技股份有限公司 关于对深圳证券交易所关注函回复的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳证券交易所： 皓宸医疗科技股份有限公司（以下简称"皓宸医疗"、"公司"或"上市 公司"）董事会于 2023 年 8 月 9 日收到深圳证券交易所上市公司管理二部下发 的《关于对皓宸医疗科技股份有限公司的关注函》（公司部关注函[2023]第 295 号）（以下简称"关注函"）。公司就关注函中所涉及事项逐一进行核 实，根据相关各方提供的资料和信息，对关注函中有关问题向深圳证券交易所 进行了回复，现将回复内容披露如下: 1、请你公司核实北京首拓是否认可上述合作协议解除事项。 回复： 公司向北京首拓融汇投资有限公司（以下简称"北京首拓融汇"或"北京 首拓"）发送了《询证函》。根据北京首拓于 2023 年 8 月 11 日回复公司的 《关于<询证函>的回复函》，北京首拓不认可上述合作协议解除事项，并主张 理由如下： "首先，北京首拓融汇未曾收悉广州汇垠澳丰股权投资基金管理有限公司 （以 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥313,632,742.87, representing a 48.04% increase compared to ¥211,861,084.40 in the same period last year[20]. - The net profit attributable to shareholders was ¥7,620,553.84, a significant turnaround from a loss of ¥30,559,032.20 in the previous year, marking a 124.94% improvement[20]. - The net cash flow from operating activities was ¥17,808,160.45, compared to a negative cash flow of ¥36,173,487.44 in the same period last year, reflecting a 149.23% increase[20]. - Basic earnings per share improved to ¥0.0091 from a loss of ¥0.0364, indicating a 125.00% increase[20]. - The company reported a comprehensive income total of ¥12,836,110.03, recovering from a loss of ¥44,792,578.57 in the previous year[140]. - The company reported a total investment in securities of 1.78 million yuan, with a fair value of 1.78 million yuan at the end of the reporting period[56]. - The company reported a total guarantee amount of 15,680,000 RMB during the reporting period, which accounts for 26.98% of the company's net assets[104]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,681,353,944.02, up 2.81% from ¥1,635,408,931.74 at the end of the previous year[20]. - The total value of restricted assets reached ¥822,907,952.37, primarily due to collateral for loans[54]. - Long-term equity investments stood at ¥592,859,048.86, accounting for 35.26% of total assets[51]. - The company reported a decrease in long-term borrowings, which were transferred to current liabilities, indicating a shift in debt structure[51]. - The total liabilities increased to CNY 1,099,764,231.06 from CNY 1,066,655,328.80, reflecting a growth of approximately 3.1%[132]. - Owner's equity totaled CNY 581,589,712.96, up from CNY 568,753,602.94, indicating an increase of about 2.9%[132]. Business Operations and Strategy - The company operates in the dental medical services and manufacturing sectors, forming a dual business model of "dental medical services + industrial manufacturing"[28]. - The company aims to expand its business throughout the Greater Bay Area, establishing itself as the leading dental medical brand in South China[34]. - The company has completed the restructuring of its operational organization to enhance management efficiency and responsiveness[35]. - The company is actively responding to national policies by adjusting its dental implant service pricing system to align with government requirements[29]. - The company plans to continue increasing coverage of new industry clients while enhancing product and service value[38]. - The company is focused on talent retention to avoid risks associated with the loss of professional medical staff, which is crucial for maintaining market competitiveness[66]. Research and Development - Research and development investment rose by 50.78% to CNY 6.43 million, compared to CNY 4.26 million in the previous year[44]. - The company aims to enhance its research and development capabilities to innovate and introduce new technologies[162]. - The company has initiated three major information technology projects to improve management efficiency and decision-making capabilities[36]. Market Presence and Customer Engagement - The company achieved a patient reception of 286,700 visits, representing a year-on-year increase of over 35%[35]. - The average patient spending for new patients increased by over 6% year-on-year[36]. - User data indicated a 20% increase in active users year-over-year, reaching a total of 1.2 million active users by the end of June 2023[152]. - The company plans to launch two new products in Q3 2023, aiming to capture an additional 15% market share in the medical technology sector[154]. Legal and Compliance Issues - The company is currently involved in legal proceedings related to a contract dispute, which may affect its financial standing[67]. - The company has frozen bank accounts due to ongoing legal matters, posing potential risks to its financial operations[68]. - The company is actively communicating with the court regarding the freezing of some bank accounts due to overdue loans[104]. - The company disclosed potential changes in control on July 5 and August 9, 2023, and will continue to monitor developments[91]. Future Outlook - Future guidance indicates a cautious but optimistic outlook, with expectations for continued revenue growth and market expansion[151]. - The management provided a revenue guidance of 1 billion yuan for the full year 2023, indicating a growth target of 50% compared to 2022[152]. - The company plans to expand its market presence and invest in new product development to drive future growth[162].

皓宸医疗科技股份有限公司关于 北京首拓融汇投资有限公司收到《受理案件通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于近日收到北京首拓融汇投 资有限公司（以下简称"北京首拓融汇"）发来的由广州市南沙区人民法院出具的 （2023）粤 0115 民初 10080 号《受理案件通知书》。广州市南沙区人民法院已受理 北京首拓融汇提出的请求确认广州汇垠澳丰股权投资基金管理有限公司（以下简 称"汇垠澳丰"）于 2023 年 8 月 4 日向北京首拓融汇发出的《关于解除<合作协议> 的函》无效一案。现将相关情况公告如下： 证券代码：002622 证券简称：皓宸医疗 公告编号：2023-034 敬请广大投资者理性投资，注意投资风险。 三、备查文件 1、广州市南沙区人民法院出具的（2023）粤 0115 民初 10080 号《受理案件通 知书》 特此公告。 1 皓宸医疗科技股份有限公司董事会 二〇二三年八月二十一日 一、《受理案件通知书》主要内容 北京首拓融汇与汇垠澳丰之间确认合同有效纠纷一案的起诉材料已收到。经 审查 ...

年度期末累计实现净利润数低于截至当期期末累计承诺净利润 数，你们应在审计机构出具审核报告之日起 15 个工作日内，以 现金方式向皓宸医疗补偿完毕。皓宸医疗有权优先以尚未支付的 交易对价抵销你们的应补偿金额，不足部分你们仍应继续以现金 进行补偿。 深 圳 证 券 交 易 所 关于对共青城德伦医疗投资管理合伙企业 （有限合伙）、黄招标、黄维通的监管函 公司部监管函〔2023〕第 135 号 共青城德伦医疗投资管理合伙企业（有限合伙）、黄招标、黄维 通： 2021 年，皓宸医疗科技股份有限公司（曾用名：融钰集团 股份有限公司，以下简称"皓宸医疗"）通过支付现金购买共青 城德伦医疗投资管理合伙企业（有限合伙）、珠海欢乐世纪股权 投资基金（有限合伙）持有的广东德伦医疗集团有限公司（曾用 名：广州德伦医疗投资有限公司，以下简称 "德伦医疗"）51% 股权。2021 年 10 月 27 日，皓宸医疗披露的《重大资产购买暨 关联交易报告书（草案）（修订稿）（以下简称《重组报告书》） 显示，你们作为业绩补偿承诺人，承诺德伦医疗 2021 年度、2022 年度和 2023 年度净利润（指合并报表范围扣除非经常性损益后 归属于母公 ...

深 圳 证 券 交 易 所 关于对皓宸医疗科技股份有限公司的关注函 公司部关注函〔2023〕第 295 号 皓宸医疗科技股份有限公司董事会： 2023 年 8 月 8 日，你公司披露的《关于公司控制权可能发 生变更的进展公告》显示，根据广州汇垠澳丰股权投资基金管理 有限公司（以下简称"汇垠澳丰"）向北京首拓融汇投资有限公 司（以下简称"北京首拓"）发送的《关于解除<合作协议>的函》， 《广州汇垠澳丰股权投资基金管理有限公司与北京首拓融汇投资 有限公司之合作协议》（以下简称"合作协议"）自《关于解除< 合作协议>的函》发出之日起解除，你公司控制权存在变更的可 能。我部对此表示关注，请你公司就以下问题做出书面说明： 1.请你公司核实北京首拓是否认可上述合作协议解除事项。 2.请你公司结合合作协议的约定，严格对照《上市公司收购 管理办法》第八十四条规定，逐条分析合作协议解除后，汇垠澳 丰能否控制你公司，公司控制权的归属情况及认定依据。 3.请说明你公司及控股股东拟采取何种措施维持你公司控 1 5.你公司认为应予以说明的其他事项。 请你公司就上述问题做出书面说明，在 2023 年 8 月 23 日前 将有关说明材料报 ...

关于公司控制权可能发生变更的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 根据广州汇垠澳丰股权投资基金管理有限公司向北京首拓融汇投资有限公 司发送的《关于解除<合作协议>的函》，《广州汇垠澳丰股权投资基金管理有 限公司与北京首拓融汇投资有限公司之合作协议》（以下简称"合作协议"） 自《关于解除<合作协议>的函》发出之日起解除。敬请广大投资者注意投资风 险。 一、前次权益变动基本情况 证券代码：002622 证券简称：皓宸医疗 公告编号：2023-033 皓宸医疗科技股份有限公司 皓宸医疗科技股份有限公司（以下简称"公司"或"上市公司"）第一大股 东广州汇垠日丰投资合伙企业（有限合伙）（以下简称"汇垠日丰"）之普通合 伙人及执行事务合伙人广州汇垠澳丰股权投资基金管理有限公司（以下简称"汇 垠澳丰"）与北京首拓融汇投资有限公司（以下简称"北京首拓融汇"）于 2020 年 2 月 10 日签署《广州汇垠澳丰股权投资基金管理有限公司与北京首拓融汇投 资有限公司之合作协议》。 根据合作协议约定，汇垠澳丰将根据北京首拓融汇的咨询意见及投资建议行 使 ...

| 投资者关系活动 | 分析师会议 □特定对象调研 □ | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | 其他 □ | | 参与单位名称及 | | | | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日（周一） 下午 2023 5 22 14:30~16:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总经理（代）陆璐 | | 员姓名 | 2、副总经理、财务总监邓强 | | | 3、董事、副总经理、董事会秘书康超 | | | 1、请问对于横向并购的考虑是怎样的呢？有无目标地域或 | | | 者收购对象呢？ | | | 尊敬的投资者，您好！未来公司将根据"广佛——珠三角 | | | ——大湾区"的发展路径稳步推进德伦品牌，并在全国其他地区 | | | 挑选当地运营不错的口腔连锁，待时机成熟后并入上市公司，同 | | | 时坚持并购后区域品牌不变、核心 ...

为进一步加强与投资者的互动交流，皓宸医疗科技股份有限公司（以下简称 "公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司 共同举办的"2023年吉林辖区上市公司网上集体业绩说明会"，现将有关事项公 告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参 与公司业绩说明会,时间为2023年5月22日（星期一）14:30至16:00。 届时公司董事长/总经理（代）陆璐女士，副总经理、财务总监邓强先生， 副总经理、董事、董事会秘书康超先生将通过网络在线问答互动的形式，与投资 者就2022年经营业绩等投资者关注的问题进行交流。期间，公司高管将全程在线， 实时回答投资者的提问。投资者可于2022年5月19日（星期五）17：00前访问 https://ir.p5w.net/zj/，进入问题征集专题页面，欢迎广大投资者积极参与。 证券代码：002622 证券简称：皓宸医疗 公告编号：2023-024 皓宸医疗科技股份有限公司 关于参加网上集体业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan in 2022, representing a year-over-year growth of 25%[19]. - The company's operating revenue for 2022 was ¥500,650,216.76, representing a 197.82% increase compared to ¥168,106,984.77 in 2021[22]. - The net profit attributable to shareholders was -¥256,788,671.99 in 2022, a decrease of 237.96% from -¥75,981,538.91 in 2021[23]. - The cash flow from operating activities increased by 75.56% to ¥32,245,101.11 in 2022, up from ¥18,367,226.36 in 2021[23]. - The basic earnings per share for 2022 was -¥0.3057, a decline of 237.79% from -¥0.0905 in 2021[23]. - The company reported a net profit attributable to shareholders of -¥256,788,671.99, a significant decrease of 237.96% year-on-year, primarily due to provisions for expected liabilities and goodwill impairment[49]. - The company reported a significant difference between net cash flow from operating activities and net profit due to provisions for litigation and accounting standards[69]. - The company reported a net profit margin of 12%, which is an improvement from 10% in the previous year[149]. - The actual net profit for 2022 was reported at CNY -44.46 million, indicating a significant shortfall compared to the commitment[162]. User Growth and Market Expansion - User data showed a growth in active users, reaching 2 million by the end of 2022, an increase of 40% compared to the previous year[19]. - User data showed a 30% increase in active users, reaching 2 million by the end of the fiscal year[116]. - The company is expanding its market presence, targeting an additional 100 clinics across China by the end of 2023[19]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market penetration by the end of the next fiscal year[116]. - The company is expanding its market presence, targeting an additional 10 provinces in China by the end of the next fiscal year[155]. Product Development and Innovation - New product development includes the launch of a cutting-edge dental service platform, expected to enhance service efficiency by 50%[19]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative medical technologies[150]. - The company is investing 200 million RMB in R&D for innovative technologies aimed at enhancing product efficiency and user experience[151]. - The company is focusing on expanding its product categories and improving market competitiveness through new product development and technology upgrades[62]. - The introduction of Insignia personalized orthodontic technology aims to enhance clinical treatment efficiency and precision[62]. Strategic Acquisitions and Investments - A strategic acquisition of Guangdong Delun Medical Group has been completed, enhancing the company's capabilities in dental services[19]. - A strategic acquisition of a local competitor was completed, expected to enhance operational efficiency and increase annual revenue by approximately 200 million RMB[116]. - The company plans to enhance its oral medical service quality management and control, ensuring standardized implementation[85]. - The company is exploring potential acquisitions to bolster its product portfolio, with a budget of up to 500 million RMB allocated for this purpose[149]. Financial Management and Governance - The board has decided not to distribute cash dividends for the fiscal year 2022, focusing on reinvestment for growth[4]. - The company has established a complete and independent financial accounting department, ensuring no shared bank accounts with shareholders[105]. - The company has a governance structure that complies with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[97]. - The company has a dedicated investor relations management system to enhance communication and transparency with investors[103]. - The company has committed to strict adherence to its promises regarding avoiding competition and managing its subsidiaries[154]. Risks and Challenges - The company faces potential risks related to market fluctuations and regulatory changes, which may impact future performance[3]. - The company is addressing potential policy risks by closely monitoring regulatory trends in the oral medical industry[86]. - The company has recognized an impairment provision of CNY 18.20 million for goodwill related to Derun Medical, leaving a carrying amount of CNY 199.67 million[164]. Social Responsibility and Community Engagement - The company has actively engaged in over 1,000 free dental check-up events and oral health lectures, reaching more than 100,000 people during the reporting period[145]. - The company has focused on social responsibility by participating in community welfare activities and supporting local education and health initiatives[145]. - The company has implemented energy-saving measures by introducing advanced technologies and gradually phasing out high-energy-consuming equipment[145]. Research and Development - The company plans to invest 200 million yuan in R&D for new medical technologies over the next two years[19]. - R&D investment increased by 47.88% to ¥14,568,436.83, but the proportion of R&D investment to operating revenue decreased to 2.91% from 5.86%[65]. - The company is conducting research on the application of digital invisible orthodontics technology for the traction of impacted teeth in adults, aiming to enhance aesthetic treatment options[63]. Employee Management and Training - The total number of employees at the end of the reporting period is 1,487, with 567 being medical staff[131]. - The company has implemented a strict compensation management system, linking employee salaries to company performance[132]. - During the reporting period, the company organized 7 training sessions focused on industry operations and compliance[133].